ENTA vs ACHV

Analysts rate Enanta Pharmaceuticals, Inc.

(ENTA) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Achieve Life Sciences, Inc.

(ACHV) delivered a total return of -50. 9%, compared to -70. 1% for Enanta Pharmaceuticals, Inc. (ENTA). Over 10 years, the gap is even starker: ENTA returned -39. 0% versus ACHV's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Enanta Pharmaceuticals, Inc.

(ENTA) is the lower-risk stock at 1. 44β versus Achieve Life Sciences, Inc. 's 2. 14β — meaning ACHV is approximately 48% more volatile than ENTA relative to the S&P 500. On balance sheet safety, Achieve Life Sciences, Inc. (ACHV) carries a lower debt/equity ratio of 70% versus 3% for Enanta Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Enanta Pharmaceuticals, Inc.

grew EPS 29. 9% year-over-year, compared to -0. 8% for Achieve Life Sciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Achieve Life Sciences, Inc.

(ACHV) is the more profitable company, earning 0. 0% net margin versus -125. 4% for Enanta Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACHV leads at 0. 0% versus -130. 7% for ENTA. At the gross margin level — before operating expenses — ENTA leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Enanta Pharmaceuticals, Inc.

(ENTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Achieve Life Sciences, Inc. (ACHV) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ENTA: -39. 0%, ACHV: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.